<DOC>
	<DOCNO>NCT01086384</DOCNO>
	<brief_summary>This study establish safety well demonstrate benefit addition LABA ICS utilizing endpoint ( time first severe asthma exacerbation ) inform safety efficacy .</brief_summary>
	<brief_title>Asthma Exacerbation Study</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Clinical diagnosis asthma Reversibility FEV1 twelve percent great two hundred milliliter great approximately ten forty minute follow two four inhalation albuterol FEV1 fifty ninety percent predict Currently use inhale corticosteroid therapy History one asthma exacerbation require treatment oral/systemic corticosteroid emergency department visit inpatient hospitalization previous year History life threaten asthma previous 5 year ( require intubation , and/or associate hypercapnia , hypoxic seizure respiratory arrest Respiratory infection oral candidiasis Uncontrolled disease clinical abnormality Allergies Taking another investigational medication prohibit medication</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>